Group 1: Acquisition Details - Prestige is expanding its consumer health portfolio by acquiring a well-known brand, which aligns with its long-term growth strategy [1] - The acquisition will be funded through cash on hand and a new term loan facility, with the transaction expected to close in the first half of fiscal 2027, pending regulatory approvals [1] - As of December 31, 2025, Prestige held $62.37 million in cash and equivalents [1] Group 2: Brand Impact - The acquisition includes Breathe Right, known for its drug-free nasal strips, which will help Prestige grow in the sleep and better-breathing categories where demand is increasing [2] - The deal also encompasses established brands like Dimetapp, commonly used in children's cough and cold treatments [2] - Management anticipates that the acquisition will enhance gross and EBITDA margins, increase free cash flow, and support long-term leverage goals [2] Group 3: Stock Performance and Technical Analysis - Currently, the stock trades 9.1% below its 20-day simple moving average and 7.6% below its 100-day average, indicating short-term weakness [3] - Over the past 12 months, shares have decreased by 28.81%, positioning the stock closer to its 52-week low than its high [3] - The RSI is at 30.25, suggesting neutral conditions, while the MACD remains negative at -1.54, indicating ongoing bearish pressure [3] Group 4: Earnings and Analyst Outlook - The next major catalyst for the stock is the estimated earnings report on May 7, 2026 [5] - The stock carries a Buy Rating with an average price target of $77.78, with recent analyst actions reflecting mixed sentiments [6][8] - Jefferies has lowered its target to $66.00, while Canaccord Genuity maintains a Buy rating with a target of $88.00 [8] Group 5: Price Action - Prestige Consumer shares fell 1.14% to close at $60.06 on Thursday [9]